Direct oral anticoagulant versus low molecular weight heparin for the treatment of cancer-associated venous thromboembolism: 2022 updated systematic review and meta-analysis of randomized controlled trials

International clinical practice guidelines have progressively endorsed direct oral anticoagulants (DOACs) as an alternative to low-molecular-weight heparins (LMWHs) monotherapy for the initial and long-term treatment of cancer-associated thrombosis (CAT). Several new randomized controlled trials (RC...

Descripción completa

Detalles Bibliográficos
Autores principales: Frere, Corinne, Farge, Dominique, Schrag, Deborah, Prata, Pedro H., Connors, Jean M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Correspondence
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9124390/
https://www.ncbi.nlm.nih.gov/pubmed/35598026
http://dx.doi.org/10.1186/s13045-022-01289-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9124390/
https://www.ncbi.nlm.nih.gov/pubmed/35598026
http://dx.doi.org/10.1186/s13045-022-01289-1

Ejemplares similares